- Under GHO’s ownership BioAgilytix has become a leader among global CRO’s following strong organic and inorganic growth – with significant investment driving expansion in operational capacity and capabilities as well as in international footprint.
- With a best of breed reputation for high-quality bioanalytical services, BioAgilytix supports the development and commercialisation of novel therapeutics to improve patient outcomes.
London, UK – Global Healthcare Opportunities, or GHO Capital Partners LLP, the European specialist investor in global healthcare, announces the realisation of its investment in portfolio company BioAgilytix to Cinven.
BioAgilytix, a leading global contract research organisation (CRO), today announced an agreement to be further capitalised by Cinven, a leading international private investment firm focused on building world-class global companies. Cinven will acquire a majority stake in BioAgilytix while current majority investor Cobepa, S.A., a Brussels-based private investment firm, will remain a significant minority investor in the Company.
Cobepa and GHO Capital, a leading specialist investor in global healthcare, acquired BioAgilytix in November of 2018 and have built the company into a recognised global leader in the contract research organisation market with a focus on large molecule bioanalytical testing. The investment by Cinven will provide BioAgilytix with increased funding and resources to meet the growing demand for its high-quality bioanalytical services, driven by its strong scientific reputation and leading expertise in supporting the development and commercialisation of novel therapeutics.
“Our focus on providing customers with industry leading scientific expertise coupled with superior service across the pharmaceutical development pathway has been our formula for success,” said Jim Datin, President and CEO of BioAgilytix. “As we move into our next chapter of our evolution, Cinven will provide the additional resources that will empower us to expand not only our geographical reach but will also enable us to invest further in our talent and facilities around the globe to meet the ever-growing needs of our customers.”
Peter Connolly, Managing Director and Head of North America of Cobepa said, “We are excited to continue working with Jim and the entire BioAgilytix management team and are thrilled to welcome Cinven as a new investor in the Company. The success of BioAgilytix is driven by its unwavering focus on both high-quality science and a customer-first orientation. These are exactly the hallmarks we seek in our investments. We look forward to partnering with Cinven and management for the next chapter of the Company’s growth.”